Featured Research

from universities, journals, and other organizations

Couples To Rely On Male Contraceptive For New Trial

Date:
May 21, 2009
Source:
University of Manchester
Summary:
Couples are being asked to replace their usual form of birth control with a new male contraceptive in a study to test its effectiveness.

Couples are being asked to replace their usual form of birth control with a new male contraceptive in a study to test its effectiveness.

Researchers at The University of Manchester, working in collaboration with nine other centres across the world, will ask men in stable relationships to take part in the trial of the hormonal contraceptive.

The research, which follows a similar trial in China published earlier this month involving testosterone injections, will involve male volunteers aged 18 to 45 being given injections of testosterone along with a second hormone that has been shown to reversibly suppress sperm production.

The combination of two hormones means the trial will require half the frequency of injections as the Chinese study. The two hormones – Norethisterone enantate and Testosterone undecanoate – have already undergone trials to test their safety and were shown to have only mild side-effects in a small number of individuals.

The trial will initially involve up to four courses of injections over six months, during which time the men’s sperm count will be measured to ensure it is below fertility levels.

The couples – 60 in Manchester and a further 340 internationally – will then be asked to rely solely on the hormonal method for 12 months while the male partner continues to receive the injections every eight weeks.

At the end of the trial period, the men’s sperm count will continue to be monitored to assess how quickly fertility levels return to normal.

Lead researcher Frederick Wu, Professor of Medicine and Endocrinology, said: “There is currently a great imbalance of contraceptive methods between men and women with almost 20 different female methods compared to only condoms and vasectomy for men.

“The World Health Organisation wants to provide more male contraceptive choices – especially reversible methods – to allow couples to better plan their families.

“We know from previous studies that any side-effects are minor, while the risk of pregnancy with this hormonal treatment is similar to that of the female pill and far less than the risks posed by using barrier methods alone.

“Couples taking part in the trial are likely to be married or in long-term relationships and may be looking for alternatives to their existing methods of contraception.’’

The study is being funded by the World Health Organisation and the Contraceptive Research and Development (CONRAD) Programme at the Eastern Virginia Medical School.


Story Source:

The above story is based on materials provided by University of Manchester. Note: Materials may be edited for content and length.


Cite This Page:

University of Manchester. "Couples To Rely On Male Contraceptive For New Trial." ScienceDaily. ScienceDaily, 21 May 2009. <www.sciencedaily.com/releases/2009/05/090520093209.htm>.
University of Manchester. (2009, May 21). Couples To Rely On Male Contraceptive For New Trial. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2009/05/090520093209.htm
University of Manchester. "Couples To Rely On Male Contraceptive For New Trial." ScienceDaily. www.sciencedaily.com/releases/2009/05/090520093209.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins